NO752650L - - Google Patents
Info
- Publication number
- NO752650L NO752650L NO752650A NO752650A NO752650L NO 752650 L NO752650 L NO 752650L NO 752650 A NO752650 A NO 752650A NO 752650 A NO752650 A NO 752650A NO 752650 L NO752650 L NO 752650L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- compound
- condensed
- fluorophenyl
- chlorophenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- -1 o-hydroxyphenyl Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000004885 piperazines Chemical class 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 150000001556 benzimidazoles Chemical class 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010047139 Vasoconstriction Diseases 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000025033 vasoconstriction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
- PARUQVNBVVOVQQ-UHFFFAOYSA-N 2-[(2-aminoanilino)methyl]phenol Chemical compound NC1=CC=CC=C1NCC1=CC=CC=C1O PARUQVNBVVOVQQ-UHFFFAOYSA-N 0.000 description 2
- ILNFSHVHMVYGNF-UHFFFAOYSA-N 2-[(2-aminophenyl)iminomethyl]phenol Chemical compound NC1=CC=CC=C1N=CC1=CC=CC=C1O ILNFSHVHMVYGNF-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JWJOLXRLRVAGCW-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-2-(4-ethylpiperazin-1-yl)-4-methylbenzimidazole Chemical compound C1CN(CC)CCN1C1=NC2=C(C)C=CC=C2N1CC1=CC=C(Cl)C=C1 JWJOLXRLRVAGCW-UHFFFAOYSA-N 0.000 description 1
- PVKCYQIQSGNJAJ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-4-methyl-2-(4-propylpiperazin-1-yl)benzimidazole Chemical compound C1CN(CCC)CCN1C1=NC2=C(C)C=CC=C2N1CC1=CC=C(F)C=C1 PVKCYQIQSGNJAJ-UHFFFAOYSA-N 0.000 description 1
- CBEHYOCPXGJPLR-UHFFFAOYSA-N 2-(chloromethyl)-1-[(4-fluorophenyl)methyl]benzimidazole Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1CCl CBEHYOCPXGJPLR-UHFFFAOYSA-N 0.000 description 1
- UMTRMDDIRQFQQJ-UHFFFAOYSA-N 2-[[2-(chloromethyl)benzimidazol-1-yl]methyl]phenol Chemical compound OC1=CC=CC=C1CN1C2=CC=CC=C2N=C1CCl UMTRMDDIRQFQQJ-UHFFFAOYSA-N 0.000 description 1
- KXHKNXDMVZMLKC-UHFFFAOYSA-N 2-[[6-(chloromethyl)-1-[(4-chlorophenyl)methyl]cyclohexa-2,4-dien-1-yl]methyl]-1h-imidazole Chemical compound ClCC1C=CC=CC1(CC=1C=CC(Cl)=CC=1)CC1=NC=CN1 KXHKNXDMVZMLKC-UHFFFAOYSA-N 0.000 description 1
- NMILGIZTAZXMTM-UHFFFAOYSA-N 4-propylmorpholine Chemical compound CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010064000 Lichenoid keratosis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- OSDZHDOKXGSWOD-UHFFFAOYSA-N nitroxyl;hydrochloride Chemical compound Cl.O=N OSDZHDOKXGSWOD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2436883A DE2436883C2 (de) | 1974-07-29 | 1974-07-29 | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO752650L true NO752650L (sv) | 1976-01-30 |
Family
ID=5922047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO752650A NO752650L (sv) | 1974-07-29 | 1975-07-28 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4011322A (sv) |
| JP (1) | JPS5136468A (sv) |
| AR (1) | AR207869A1 (sv) |
| AT (1) | AT346336B (sv) |
| AU (1) | AU8347175A (sv) |
| BE (1) | BE831856A (sv) |
| BG (1) | BG26374A3 (sv) |
| CA (1) | CA1065866A (sv) |
| CH (1) | CH615924A5 (sv) |
| CS (1) | CS189713B2 (sv) |
| DD (1) | DD122536A5 (sv) |
| DE (1) | DE2436883C2 (sv) |
| DK (1) | DK140634B (sv) |
| ES (1) | ES439811A1 (sv) |
| FI (1) | FI752152A (sv) |
| FR (1) | FR2280380A1 (sv) |
| GB (1) | GB1520262A (sv) |
| HU (1) | HU170517B (sv) |
| IE (1) | IE41503B1 (sv) |
| IL (1) | IL47769A (sv) |
| NL (1) | NL7509061A (sv) |
| NO (1) | NO752650L (sv) |
| SE (1) | SE7508544L (sv) |
| SU (1) | SU626698A3 (sv) |
| ZA (1) | ZA754884B (sv) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| JPS59199679A (ja) * | 1983-04-27 | 1984-11-12 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
| DK0632717T3 (da) * | 1992-03-23 | 1999-02-22 | Janssen Pharmaceutica Nv | Middel til anvendelse som et anti-irritationsmiddel |
| DE102006007773B4 (de) * | 2006-02-20 | 2010-02-11 | Walter Dr. Kothe | Anordnung zum Spalten von Wasser |
| US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| US9061010B2 (en) * | 2007-09-18 | 2015-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection |
| US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US8729108B2 (en) * | 2008-06-17 | 2014-05-20 | Christopher J Dannaker | Waterborne topical compositions for the delivery of active ingredients such as azelaic acid |
| JP2012520884A (ja) * | 2009-03-18 | 2012-09-10 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー | フラビウイルス科ウイルス感染症を治療する方法および組成物 |
| PT2552449T (pt) | 2010-03-26 | 2017-06-12 | Galderma Res & Dev | Composições que compreendem brimonidina para o tratamento de eritema |
| MX2014004383A (es) | 2011-10-19 | 2014-11-12 | Galderma Sa | Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5. |
| SI3035926T1 (sl) | 2013-08-19 | 2020-11-30 | The Regents Of The University Of California | Spojine in postopki za zdravljenje epileptičnih motenj |
| PT3261640T (pt) | 2015-02-25 | 2022-07-06 | Univ California | Agonistas de 5ht para tratamento de distúrbios de epilepsia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620449C3 (de) * | 1964-07-23 | 1974-02-21 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Substituierte Benzimidazole und Verfahren zu ihrer Herstellung |
| GB1209558A (en) * | 1968-07-06 | 1970-10-21 | Delalande Sa | Derivatives of 5-cinnamoyl benzofuran and process for their preparation |
-
1974
- 1974-07-29 DE DE2436883A patent/DE2436883C2/de not_active Expired
-
1975
- 1975-01-01 AR AR259784A patent/AR207869A1/es active
- 1975-07-17 CS CS755082A patent/CS189713B2/cs unknown
- 1975-07-23 IE IE1648/75A patent/IE41503B1/en unknown
- 1975-07-23 IL IL47769A patent/IL47769A/xx unknown
- 1975-07-24 SU SU752159081A patent/SU626698A3/ru active
- 1975-07-25 DD DD187479A patent/DD122536A5/xx unknown
- 1975-07-28 NO NO752650A patent/NO752650L/no unknown
- 1975-07-28 FI FI752152A patent/FI752152A/fi not_active Application Discontinuation
- 1975-07-28 HU HUSC527A patent/HU170517B/hu unknown
- 1975-07-28 US US05/599,398 patent/US4011322A/en not_active Expired - Lifetime
- 1975-07-28 BG BG7530663A patent/BG26374A3/xx unknown
- 1975-07-28 SE SE7508544A patent/SE7508544L/sv unknown
- 1975-07-28 AT AT583775A patent/AT346336B/de not_active IP Right Cessation
- 1975-07-29 JP JP50092463A patent/JPS5136468A/ja active Pending
- 1975-07-29 AU AU83471/75A patent/AU8347175A/en not_active Expired
- 1975-07-29 GB GB31671/75A patent/GB1520262A/en not_active Expired
- 1975-07-29 ES ES439811A patent/ES439811A1/es not_active Expired
- 1975-07-29 ZA ZA00754884A patent/ZA754884B/xx unknown
- 1975-07-29 CA CA232,438A patent/CA1065866A/en not_active Expired
- 1975-07-29 NL NL7509061A patent/NL7509061A/xx not_active Application Discontinuation
- 1975-07-29 CH CH989775A patent/CH615924A5/de not_active IP Right Cessation
- 1975-07-29 DK DK344575AA patent/DK140634B/da not_active Application Discontinuation
- 1975-07-29 BE BE158719A patent/BE831856A/xx unknown
- 1975-07-29 FR FR7523605A patent/FR2280380A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| SU626698A3 (ru) | 1978-09-30 |
| BE831856A (fr) | 1976-01-29 |
| ATA583775A (de) | 1978-03-15 |
| IE41503B1 (en) | 1980-01-16 |
| IL47769A0 (en) | 1975-10-15 |
| CA1065866A (en) | 1979-11-06 |
| DK140634B (da) | 1979-10-15 |
| AR207869A1 (es) | 1976-11-08 |
| BG26374A3 (sv) | 1979-03-15 |
| AU8347175A (en) | 1977-02-03 |
| GB1520262A (en) | 1978-08-02 |
| DK344575A (sv) | 1976-01-30 |
| NL7509061A (nl) | 1976-02-02 |
| CH615924A5 (sv) | 1980-02-29 |
| FI752152A (sv) | 1976-01-30 |
| ES439811A1 (es) | 1977-04-16 |
| IE41503L (en) | 1976-01-29 |
| US4011322A (en) | 1977-03-08 |
| DD122536A5 (sv) | 1976-10-12 |
| IL47769A (en) | 1978-10-31 |
| AT346336B (de) | 1978-11-10 |
| JPS5136468A (sv) | 1976-03-27 |
| ZA754884B (en) | 1976-06-30 |
| CS189713B2 (en) | 1979-04-30 |
| DK140634C (sv) | 1980-03-10 |
| DE2436883A1 (de) | 1976-02-19 |
| DE2436883C2 (de) | 1985-08-22 |
| FR2280380A1 (fr) | 1976-02-27 |
| HU170517B (sv) | 1977-06-28 |
| FR2280380B1 (sv) | 1980-04-30 |
| SE7508544L (sv) | 1976-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO752650L (sv) | ||
| KR850000883B1 (ko) | 삼-치환 이미다졸 유도체의 제조방법 | |
| US4407824A (en) | Pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids, novel carboxylic acid salts and the production thereof | |
| FR2555584A1 (fr) | Derives de l'acide fluoro-6-dihydro-1,4-oxo-4-piperazinyl substitue-7-quinoline-carboxylique-3 et procede pour leur preparation et compositions pharmaceutiques a action anti-bacteriennes a base desdits derives | |
| NZ238407A (en) | 5-hydroxy-2-(substituted methyl)amino pyridine derivatives and pharmaceuticals compositions | |
| US5229378A (en) | Glycyrrhetic acid derivatives | |
| NZ194328A (en) | 3-amino-1-(phenyl or pyridyl)-2-pyrazolines:pharmaceutical compositions | |
| TWI383795B (zh) | 皮膚炎治療劑 | |
| NO141207B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive fenylalkylaminer | |
| FR2705095A1 (fr) | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| US4970301A (en) | 2-(piperazinyl)-2-oxoethylene-substituted flavonoid compounds | |
| US20140275266A1 (en) | Prostanoid receptor agonist compounds and methods of use for same | |
| FR2472561A1 (fr) | Derives de l'acide 4-guanidinomethylcyclohexane carboxylique, leur procede de preparation et leur application en therapeutique | |
| NO824335L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive fenolestere. | |
| FR2666583A1 (fr) | Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant. | |
| NO793578L (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive trifenylalkenderivater | |
| EP0079639B1 (en) | A new anti-inflammatory drug | |
| CA2278660A1 (en) | Hydroquinone derivatives | |
| DK158944B (da) | Analogifremgangsmaade til fremstilling af substituerede methylimidazolforbindelser | |
| CA2166032A1 (fr) | Derives de 1-oxo-2-(phenylsulfonylamino) pentylpiperidine, leur preparation et leur application en therapeutique | |
| US4259335A (en) | 1-Methyl-4-piperidinol esters of 4-quinolinylamino benzoates and antiinflammatory and analgesic compositions and methods employing them | |
| US4256753A (en) | 4-(2-Pyridylamino)phenylacetic acid derivatives | |
| EP0496746A1 (en) | Pharmaceutically active amino-substituted heteroaryl amines | |
| KR20240036571A (ko) | 치료 화합물 및 방법 | |
| EP0720608B1 (de) | Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |